Files
Document type
ArticleVersion
Accepted versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/162264
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
Journal Title
Authors
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Insulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) development. Preclinical evidence suggests that peroxisome proliferator-activated receptor (PPAR) β/δ activators may prevent and treat obesity-induced insulin resistance and T2DM, while clinical trials highlight their potential utility in dyslipidemia. This review summarizes recent mechanistic insights into the antidiabetic effects of PPARβ/δ activators, including their anti-inflammatory actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as their capacity to activate pathways that are also stimulated by exercise. Findings from clinical trials are also examined. Dissecting the effects of PPARβ/δ ligands on insulin sensitivity and atherogenesis may provide a basis for the development of therapies for the prevention and treatment of T2DM and cardiovascular disease (CVD).
Subject
Subject (English)
Citation
Citation
VÁZQUEZ CARRERA, Manuel. Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. Trends in Endocrinology and Metabolism. 2016. Vol. 27, num. 5, pags. 319-334. ISSN 1043-2760. [consulted: 10 of June of 2026]. Available at: https://hdl.handle.net/2445/162264